Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma

American Journal of Pathology

Volumn 178, Issue 2, 2011, Pages 881-894

  Jean, Didier ^a,b   Thomas, Emilie ^c   Manié, Elodie ^d,e   Renier, Annie ^a,b   De Reynies, Aurélien ^c   Lecomte, Céline ^f   Andujar, Pascal ^g,h,i   Fleury Feith, Jocelyne ^j,k   Galateau Sallé, Françoise ^a,l   Giovannini, Marco ^m   Zucman Rossi, Jessica ^a,b   Stern, Marc Henri ^d,e   Jaurand, Marie Claude ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Center de Recherche des Cordeliers   (France)

^d INSTITUT CURIE   (France)

^e INSTITUT CURIE   (France)

^f UNIVERSITÉ DU HAVRE   (France)

^g CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^h INSERM U955   (France)

ⁱ FACULTÉ DE MÉDECINE   (France)

^j HÔPITAL TENON   (France)

^k SORBONNE UNIVERSITÉ   (France)

^l CHU CÔTE DE NACRE   (France)

^m HOUSE EAR INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; MICRORNA; PROTEIN P21;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CARCINOGENICITY; CHROMOSOME 13Q; CHROMOSOME 14Q; CHROMOSOME 1P; CHROMOSOME 22; CHROMOSOME 5P; CHROMOSOME ABERRATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE LOCATION; GENE LOCUS; GENE LOSS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; GENOMIC INSTABILITY; GENOMICS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MALE; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 79951836792     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2010.10.039     Document Type: Article

References (77)

1. Robinson BW, Lake RA: Advances in malignant mesothelioma. N Engl J Med 2005, 353:1591-1603 (Pubitemid 41434638)
2. Goldberg M, Imbernon E, Rolland P, Gilg Soit Ilg A, Saves M, de Quillacq A, Frenay C, Chamming S, Arveux P, Boutin C, Launoy G, Pairon JC, Astoul P, Galateau-Salle F, Brochard P: The French National Mesothelioma Surveillance Program. Occup Environ Med 2006, 63:390-395 (Pubitemid 43828903)
3. Mowe G, Gylseth B: Occupational exposure and regional variation of malignant mesothelioma in Norway, 1970-79. Am J Ind Med 1986, 9:323-332
4. Albin M, Magnani C, Krstev S, Rapiti E, Shefer I: Asbestos and cancer: an overview of current trends in Europe. Environ Health Perspect 1999, 107(Suppl 2):289-298 (Pubitemid 29264037)
5. Kishimoto T, Ozaki S, Kato K, Nishi H, Genba K: Malignant pleural mesothelioma in parts of Japan in relationship to asbestos exposure. Ind Health 2004, 42:435-439 (Pubitemid 39468823)
6. Park EK, Hannaford-Turner KM, Hyland RA, Johnson AR, Yates DH: Asbestos-related occupational lung diseases in NSW. Australia and potential exposure of the general population. Ind Health 2008, 46:535-540
7. Pan XL, Day HW, Wang W, Beckett LA, Schenker MB: Residential proximity to naturally occurring asbestos and mesothelioma risk in California. Am J Respir Crit Care Med 2005, 172:1019-1025 (Pubitemid 41476540)
8. Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK: The risk of secondary malignancies over 30 years after the treatment of non- Hodgkin lymphoma. Cancer 2006, 107:108-115 (Pubitemid 43939037)
9. Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, Hall P, Langmark F, Pukkala E, Andersson M, Kaijser M, Joensuu H, Fossa SD, Travis LB: Long-term solid cancer risk among 5-year survivors of Hodgkin's lymphoma. J Clin Oncol 2007, 25:1489-1497 (Pubitemid 46759253)
10. Goodman JE, Nascarella MA, Valberg PA: Ionizing radiation: a risk factor for mesothelioma. Cancer Causes Control 2009, 20:1237-1254
11. Goldberg S, Rey G, Luce D, Gilg Soit Ilg A, Rolland P, Brochard P, Imbernon E, Goldberg M: Possible effect of environmental exposure to asbestos on geographical variation in mesothelioma rates. Occup Environ Med 2010, 67:417-421
12. Ryman-Rasmussen JP, Tewksbury EW, Moss OR, Cesta MF, Wong BA, Bonner JC: Inhaled multiwalled carbon nanotubes potentiate airway fibrosis in murine allergic asthma. Am J Respir Cell Mol Biol 2009, 40:349-358
13. Donaldson K, Murphy FA, Duffin R, Poland CA: Asbestos, carbon nanotubes and the pleural mesothelium: a review and the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Part Fibre Toxicol 2010, 7:5
14. Poland CA, Duffin R, Kinloch I, Maynard A, Wallace WA, Seaton A, Stone V, Brown S, Macnee W, Donaldson K: Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 2008, 3:423-428
15. Takagi A, Hirose A, Nishimura T, Fukumori N, Ogata A, Ohashi N, Kitajima S, Kanno J: Induction of mesothelioma in p53+/- mouse by intraperitoneal application of multi-wall carbon nanotube. J Toxicol Sci 2008, 33:105-116 (Pubitemid 351340768)
16. Sakamoto Y, Nakae D, Fukumori N, Tayama K, Maekawa A, Imai K, Hirose A, Nishimura T, Ohashi N, Ogata A: Induction of mesothelioma by a single intrascrotal administration of multi-wall carbon nanotube in intact male Fischer 344 rats. J Toxicol Sci 2009, 34:65-76
17. Gibas Z, Li FP, Antman KH, Bernal S, Stahel R, Sandberg AA: Chromosome changes in malignant mesothelioma. Cancer Genet Cytogenet 1986, 20:191-201 (Pubitemid 16153273)
18. Hagemeijer A, Versnel MA, Van Drunen E, Moret M, Bouts MJ, Van der Kwast TH, Hoogsteden HC: Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 1990, 47:1-28 (Pubitemid 20223634)
19. Kivipensas P, Bjorkqvist AM, Karhu R, Pelin K, Linnainmaa K, Tammilehto L, Mattson K, Kallioniemi QP, Knuutila S: Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. Cancer Genet Cytogenet 1996, 89:7-13 (Pubitemid 26243648)
20. De Rienzo A, Balsara BR, Apostolou S, Jhanwar SC, Testa JR: Loss of heterozygosity analysis defines a 3-cM region of 15q commonly deleted in human malignant mesothelioma. Oncogene 2001, 20:6245-6249 (Pubitemid 32964438)
21. Krisman M, Müller KM, Jaworska M, Johnen G: Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases. J Pathol 2002, 197:363-371 (Pubitemid 34778307)
22. Lindholm PM, Salmenkivi K, Vauhkonen H, Nicholson AG, Anttila S, Kinnula VL, Knuutila S: Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH. Cytogenet Genome Res 2007, 119:46-52
23. Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K, Ueda Y, Mitsudomi T, Horio Y, Hida T, Yatabe Y, Seto M, Sekido Y: Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 2007, 98:438-446
24. Ivanov SV, Miller J, Lucito R, Tang C, Ivanova AV, Pei J, Carbone M, Cruz C, Beck A, Webb C, Nonaka D, Testa JR, Pass HI: Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer 2009, 124:589-599
25. Cheung M, Pei J, Pei Y, Jhanwar SC, Pass HI, Testa JR: The promyelocytic leukemia zinc-finger gene, PLZF, is frequently downregulated in malignant mesothelioma cells and contributes to cell survival. Oncogene 2010, 29:1633-1640
26. Christensen BC, Houseman EA, Poage GM, Godleski JJ, Bueno R, Sugarbaker DJ, Wiencke JK, Nelson HH, Marsit CJ, Kelsey KT: Integrated profiling reveals a global correlation between epigenetic and genetic alterations in mesothelioma. Cancer Res 2010, 70:5686-5694
27. Sekido Y, Pass HI, Bader S, Mew DJ, Christmas MF, Gazdar AF: Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995, 55:1227-1231
28. Xiao S, Li DZ, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA: Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995, 11:511-515
29. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT: Alterations of the p16INK4 locus in human malignant mesothelial tumors. Carcinogenesis 2002, 23:1127-1130 (Pubitemid 34814769)
30. Kitamura F, Araki S, Suzuki Y, Yokoyama K, Tanigawa T, Iwasaki R: Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients. Ind Health 2002, 40:175-181 (Pubitemid 34496365)
31. Fleury-Feith J, Lecomte C, Renier A, Matrat M, Kheuang L, Abramowski V, Levy F, Janin A, Giovannini M, Jaurand MC: Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene 2003, 22:3799-3805 (Pubitemid 36760742)
32. Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, McClatchey AI, Kane AB, Testa JR: A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 2005, 65:8090-8095 (Pubitemid 41330570)
33. Kane AB: Animal models of malignant mesothelioma. Inhal Toxicol 2006, 18:1001-1004
34. Lecomte C, Andujar P, Renier A, Kheuang L, Abramowski V, Mellottee L, Fleury-Feith J, Zucman-Rossi J, Giovannini M, Jaurand MC: Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Cell Cycle 2005, 4:1862-1869 (Pubitemid 41827334)
35. Andujar P, Lecomte C, Renier A, Fleury-Feith J, Kheuang L, Daubriac J, Janin A, Jaurand MC: Clinico-pathological features and somatic gene alterations in refractory ceramic fibre-induced murine mesothelioma reveal mineral fibre-induced mesothelioma identities. Carcinogenesis 2007, 28:1599-1605 (Pubitemid 47241811)
36. Altomare DA, Menges CW, Pei J, Zhang L, Skele-Stump KL, Carbone M, Kane AB, Testa JR: Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Proc Natl Acad Sci U S A 2009, 106:3420-3425
37. Hu Q, Akatsuka S, Yamashita Y, Ohara H, Nagai H, Okazaki Y, Takahashi T, Toyokuni S: Homozygous deletion of CDKN2A/2B is a hallmark of iron-induced high-grade rat mesothelioma. Lab Invest 2010, 90:360-373
38. Pairon JC, Orlowski E, Iwatsubo Y, Billongalland MA, Dufour G, Chammings S, Archambault C, Bignon J, Brochard P: Pleural mesothelioma and exposure to asbestos - evaluation from work histories and analysis of asbestos bodies in bronchoalveolar lavage fluid or lung tissue in 131 patients. Occup Environ Med 1994, 51:244-249 (Pubitemid 24135739)
39. dos Santos NR, Rickman DS, de Reynies A, Cormier F, Williame M, Blanchard C, Stern MH, Ghysdael J: Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. Blood 2007, 109:3972-3981
40. Mariani O, Brennetot C, Coindre JM, Gruel N, Ganem C, Delattre O, Stern MH, Aurias A: JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell 2007, 11:361-374 (Pubitemid 46518313)
41. Neuvial P, Hupe P, Brito I, Liva S, Manie E, Brennetot C, Radvanyi F, Aurias A, Barillot E: Spatial normalization of array-CGH data. BMC Bioinformatics 2006, 7:264
42. La Rosa P, Viara E, Hupe P, Pierron G, Liva S, Neuvial P, Brito I, Lair S, Servant N, Robine N, Manie E, Brennetot C, Janoueix-Lerosey I, Raynal V, Gruel N, Rouveirol C, Stransky N, Stern MH, Delattre O, Aurias A, Radvanyi F, Barillot E: VAMP: visualization and analysis of array-CGH, transcriptome and other molecular profiles. Bioinformatics 2006, 22:2066-2073 (Pubitemid 44390895)
43. Hupe P, Stransky N, Thiery JP, Radvanyi F, Barillot E: Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics 2004, 20:3413-3422 (Pubitemid 40136776)
44. Vivo C, Liu J, Broaddus C: c-jun N-terminal kinase contributes to apoptotic synergy induced by tumor necrosis factor-related apoptosis- inducing ligand plus DNA damage in chemoresistant, p53 inactive mesothelioma cells. J Biol Chem 2003, 278:25461-25467 (Pubitemid 36835297)
45. Knuutila S, Armengol G, Bjorkqvist AM, el-Rifai W, Larramendy ML, Monni O, Szymanska J: Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity. Cancer Genet Cytogenet 1998, 100:25-30 (Pubitemid 128766338)
46. Balsara BR, Bell DW, Sonoda G, De Rienzo A, du Manoir S, Jhanwar SC, Testa JR: Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. Cancer Res 1999, 59:450-454 (Pubitemid 29048882)
47. Sandberg AA, Bridge JA: Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma Cancer Genet Cytogenet 2001, 127:93-110 (Pubitemid 32586066)
48. Gray SG, Fennell DA, Mutti L, O'Byrne KJ: In arrayed ranks: array technology in the study of mesothelioma. J Thorac Oncol 2009, 4:411-425
49. Aerssens J, Guo C, Vermeesch J, Baens M, Browne D, Litt M, Van Den Berghe H, Marynen P: A physical map of the region spanning the chromosome 12 translocation breakpoint in a mesothelioma with a t(X;12)(q22;p13). Cytogenet Cell Genet 1995, 71:268-275
50. Prins JB, Williamson KA, Kamp MM, Van Hezik EJ, Van der Kwast TH, Hagemeijer A, Versnel MA: The gene for the cyclin-dependent-kinase- 4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998, 75:649-653 (Pubitemid 28094115)
51. Ladanyi M: Implications of P16/CDKN2A deletion in pleural mesotheliomas. Lung Cancer 2005, 49(Suppl 1):S95-S98
52. Kindler HL, Burris HA 3rd, Sandler AB, Oliff IA: A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer. Invest New Drugs 2009, 27:75-81
53. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR: Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res 1993, 53:4349-4355 (Pubitemid 24146789)
54. Lee WC, Testa JR: Somatic genetic alterations in human malignant mesothelioma (review). Int J Cancer 1999, 14:181-188
55. Tiainen M, Tammilehto L, Rautonen J, Tuomi T, Mattson K, Knuutila S: Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br J Cancer 1989, 60:618-626 (Pubitemid 19251463)
56. Bagchi A, Papazoglu C, Wu Y, Capurso D, Brodt M, Francis D, Bredel M, Vogel H, Mills AA: CHD5 is a tumor suppressor at human 1p36. Cell 2007, 128:459-475 (Pubitemid 46198889)
57. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, Maris JM, White PS, Brodeur GM: CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 2008, 100:940-949 (Pubitemid 351957513)
58. Mulero-Navarro S, Esteller M: Chromatin remodeling factor CHD5 is silenced by promoter CpG island hypermethylation in human cancer. Epigenetics 2008, 3:210-215
59. Berx G, van Roy F: Involvement of members of the cadherin super-family in cancer. Cold Spring Harb Perspect Biol 2009, 1:a003129
60. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW: Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806
61. Popov VM, Wu K, Zhou J, Powell MJ, Mardon G, Wang C, Pestell RG: The Dachshund gene in development and hormone-responsive tumorigenesis. Trends Endocrinol Metab 2010, 21:41-49
62. Kumaki F, Kawai T, Churg A, Galateau-Salle FB, Hasleton P, Henderson D, Roggli V, Travis WD, Cagle PT, Ferrans VJ: Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol 2002, 26:365-370 (Pubitemid 34184461)
63. Villa R, Daidone MG, Motta R, Venturini L, De Marco C, Vannelli A, Kusamura S, Baratti D, Deraco M, Costa A, Reddel RR, Zaffaroni N: Multiple mechanisms of telomere maintenance exist and differentially affect clinical outcome in diffuse malignant peritoneal mesothelioma. Clin Cancer Res 2008, 14:4134-4140
64. Rangarajan A, Weinberg RA: Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 2003, 3:952-959 (Pubitemid 37500180)
65. Baser ME, De Rienzo A, Altomare D, Balsara BR, Hedrick NM, Gutmann DH, Pitts LH, Jackler RK, Testa JR: Neurofibromatosis 2 and malignant mesothelioma. Neurology 2002, 59:290-291 (Pubitemid 34779196)
66. Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van der Valk M, van de Vijver M, Berns A: A conditional mouse model for malignant mesothelioma. Cancer Cell 2008, 13:261-271 (Pubitemid 351318370)
67. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, Buchholz E, Manegold C, Lahm H: Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma Lung Cancer 2006, 54:109-116
68. Hesson LB, Cooper WN, Latif F: Evaluation of the 3p21.3 tumour-suppressor gene cluster. Oncogene 2007, 26:7283-7301 (Pubitemid 350115980)
69. Christensen BC, Godleski JJ, Marsit CJ, Houseman EA, Lopez-Fagundo CY, Longacker JL, Bueno R, Sugarbaker DJ, Nelson HH, Kelsey KT: Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 2008, 29:1555-1559
70. Opitz I, Soltermann A, Abaecherli M, Hinterberger M, Probst-Hensch N, Stahel R, Moch H, Weder W: PTEN expression is a strong predictor of survival in mesothelioma patients. Eur J Cardiothorac Surg 2008, 33:502-506
71. Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, Knuutila S: CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma - a miRNA microarray analysis. Genes Chromosomes Cancer 2009, 48:615-623
72. Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, Murer B, Mutti L, Pierotti M, Gaudino G: MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 2010, 42:312-319
73. Ivanov SV, Goparaju CM, Lopez P, Zavadil J, Toren-Haritan G, Rosenwald S, Hoshen M, Chajut A, Cohen D, Pass HI: Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem 2010, 285:22809-22817
74. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T, Pejavar S, Mehta K, Carroll P, Simko JP, Waldman FM: Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005, 11:7012-7022 (Pubitemid 41428761)
75. Chan MW, Hui AB, Yip SK, Ng CF, Lo KW, Tong JH, Chan AW, Cheung HY, Wong WS, Chan PS, Lai FM, To KF: Progressive increase of genetic alteration in urinary bladder cancer by combined allelo-typing analysis and comparative genomic hybridization. Int J Oncol 2009, 34:963-970
76. Bjorkqvist AM, Wolf M, Nordling S, Tammilehto L, Knuuttila A, Kere J, Mattson K, Knuutila S: Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis. Br J Cancer 1999, 81:1111-1115
77. Sugarbaker DJ, Richards WG, Gordon GJ, Dong L, De Rienzo A, Maulik G, Glickman JN, Chirieac LR, Hartman ML, Taillon BE, Du L, Bouffard P, Kingsmore SF, Miller NA, Farmer AD, Jensen RV, Gullans SR, Bueno R: Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci U S A: 2008, 105:3521-3526 (Pubitemid 351723585)